Diana L Silva-Velasco

Dr. Diana L Silva-Velasco

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
DSDiana L Silva-Velasco
Diana L Silva-Velasco
EHEnrique Hong
Enrique Hong
JBJesus H. Beltran-Ornelas
Jesus H. Beltran-Ornelas
ASAraceli Sánchez-López
Araceli Sánchez-López
SCSaúl Huerta de la Cruz
Saúl Huerta de la Cruz
David CenturiónDavid Centurión
David Centurión

16 November 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
SRStephanie Randar
Stephanie Randar
DSDiana L Silva-Velasco
Diana L Silva-Velasco
FPFernanda Priviero
Fernanda Priviero
Clinton WebbClinton Webb
Clinton Webb
The small GTPase RhoA and its downstream effector Rho-kinase (ROCK) have emerged as pivotal regulators of vascular smooth muscle cell (VSMC) contraction, endothelial function, and vascular remodeling. Activation of the RhoA/ROCK pathway enhances calcium (Ca2+) sensitivity by inhibiting myosin light chain phosphatase (MLCP), thereby promoting sustained vascular tone independent of intracellular Ca2+ levels. In endothelial cells (ECs), RhoA/ROCK signaling contributes to nitric oxide (NO) dysregulation, oxidative stress, cytoskeletal reorganization, and inflammatory activation. Cumulative evidence implicates this pathway in the development and progression of hypertension and other cardiovascular diseases, where maladaptive vascular remodeling, VSMC proliferation, and endothelial dysfunction drive increased vascular resistance. Translational studies have identified ROCK inhibitors and indirect modulators such as statins as promising therapeutic strategies. This review integrates recent mechanistic insights into RhoA/ROCK regulation of vascular function with clinical and translational perspectives on targeting this pathway in hypertension.

26 May 2026
Verified
Book Chapter
Closed access
DSDiana L Silva-Velasco
Diana L Silva-Velasco
RPRinaldo R. Dos Passos
Rinaldo R. Dos Passos
RMRaiana Anjos Moraes
Raiana Anjos Moraes
TGTiago Tomazini Gonçalves
Tiago Tomazini Gonçalves
SWStephanie Wilczynski
Stephanie Wilczynski
Clinton WebbClinton Webb
Clinton Webb

6 November 2025 in Cells
Verified
Journal Article
Open access
PDF file
RMRaiana dos Anjos Moraes
Raiana dos Anjos Moraes
OAOlufunke O. Arishe
Olufunke O. Arishe
JPJames Pratt
James Pratt
SWStephanie Wilczynski
Stephanie Wilczynski
RPRinaldo Rodrigues dos Passos
Rinaldo Rodrigues dos Passos
FPFernanda Priviero
Fernanda Priviero
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase expressed in smooth muscle cells (SMCs), with emerging roles in regulating contraction. We hypothesize that PLK1 contributes to smooth muscle contractility in pudendal arteries (PA), small mesenteric arteries (SMA), and the corpus cavernosum (CC). Using male C57BL/6J mice, we assessed mRNA and protein expression of PLK1 in these tissues. In addition, the arteries and CC were mounted in myographs for isometric force measurement. We then investigated whether PLK1 regulates SMC contractility induced by phenylephrine (PE), U46619, and angiotensin II (Ang II) in arteries, and by PE, serotonin (5-HT), and electrical field stimulation (EFS; 1–16 Hz) in the CC, both in the presence and absence of the PLK1 inhibitor volasertib. PLK1 expression was confirmed in the SMA, PA, and CC by RT-qPCR or Western blotting. Notably, PLK1 inhibition significantly reduced Ang II-induced contraction in the PA and SMA and attenuated EFS-induced contraction at 2 and 4 Hz in the CC. In contrast, responses to PE, U46619, and 5-HT were unaffected by PLK1 inhibition. These results suggest that PLK1 selectively mediates contraction in response to Ang II and neurogenic stimuli. PLK1 may therefore represent a novel, stimulus-specific regulator of vascular and erectile smooth muscle contractility.

26 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ZYZeynep Elif Yesilyurt
Zeynep Elif Yesilyurt
JMJan Matthes
Jan Matthes
EHEdith Hintermann
Edith Hintermann
TCTamara Rodrigues Castaneda
Tamara Rodrigues Castaneda
RERalf Elvert
Ralf Elvert
Martin MichelMartin Michel
Martin Michel
The urinary bladder is markedly enlarged in the type 1 diabetes mellitus model of streptozotocin (STZ)-injected rats, but much less data exist for models of type 2 diabetes (T2DM). Diabetic polyuria has been proposed to explain bladder enlargement. We have collected data on bladder weight and blood glucose from 16 studies representing 9 distinct rodent diabetes (7 T2DM) and obesity models; some included arms with diets and/or pharmacological treatments. Data were analyzed for bladder enlargement and for correlations between bladder weight on the one and glucose levels on the other hand. Our data confirm major bladder enlargements in STZ rats, minor if any enlargement in fructose-fed rats, db/db mice and mice on a high-fat diet. For the first time we report bladder weight data on 5 other models with presence and degree of bladder enlargement being heterogeneous across models. Bladder weight was correlated with plasma glucose in some but not other models, but correlations were moderate to weak except for RIP-LMCV mice. We conclude that the presence and extent of bladder enlargement varies markedly across diabetes models, particularly TD2M models; our data do not support the idea that bladder enlargement is primarily driven by glucose levels/glucosuria.

15 February 2026 in American Journal of Hypertension
Verified
Journal Article
Closed access
RMRaiana dos Anjos Moraes
Raiana dos Anjos Moraes
TGTiago Tomazini Gonçalves
Tiago Tomazini Gonçalves
DSDiana L Silva-Velasco
Diana L Silva-Velasco
RPRinaldo Rodrigues dos Passos
Rinaldo Rodrigues dos Passos
FPFernanda Priviero
Fernanda Priviero